Inhibition of nocturnal acid secretion in duodenal ulcer patients by an H-2 histamine antagonist-cimetidine. A controlled double-blind investigation.
A new H-2-receptor antagonist, cimetidine, was tested as to its ability to suppress overnight gastric acid secretion in 8 male duodenal ulcer patients. In a double-blind controlled investigation, each volunteer was studied during four consecutive nights. In randomized order they received either 100, 200, or 300 mg of cimetidine or a placebo. No untoward clinical orlaboratory effects of the drug were found. Single-dose oral administration of 300 mg cimetidine caused a significant (P less than 0.05) inhibition of overnight gastric acid secretion for an 8-hr period, with the intragastric pH staying between 3.5-6.0. Cimetidine, because of its potent gastric acid inhibitory effect, may become an important therapeutic agent in the management of peptic ulcer disease.
D000284:Administration, Oral; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000187:drug effects* / Q000378:metabolism; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011955:Receptors, Drug / Q000187:drug effects
D006146:Guanidines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D010919:Placebos; D011955:Receptors, Drug